Literature DB >> 21081598

Orphan drug pricing may warrant a competition law investigation.

Jonathan C P Roos1, Hanna I Hyry, Timothy M Cox.   

Abstract

Mesh：

Year:  2010        PMID： 21081598     DOI： 10.1136/bmj.c6471

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  19 in total

1.  Time to revisit the orphan drug law.

Authors:  Silvio Garattini
Journal:  Eur J Clin Pharmacol       Date:  2011-08-13       Impact factor: 2.953

Review 2.  Unintended effects of orphan product designation for rare neurological diseases.

Authors:  Sinéad M Murphy; Araya Puwanant; Robert C Griggs
Journal:  Ann Neurol       Date:  2012-10       Impact factor: 10.422

3.  Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?

Authors:  Wills Hughes-Wilson; Ana Palma; Ad Schuurman; Steven Simoens
Journal:  Orphanet J Rare Dis       Date:  2012-09-26       Impact factor: 4.123

4.  Gaucher disease: clinical profile and therapeutic developments.

Authors:  Timothy M Cox
Journal:  Biologics       Date:  2010-12-06

5.  Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?

Authors:  Anne E M Brabers; Ellen H M Moors; Sonja van Weely; Remco L A de Vrueh
Journal:  Orphanet J Rare Dis       Date:  2011-09-05       Impact factor: 4.123

6.  The prevalence and cost of unapproved uses of top-selling orphan drugs.

Authors:  Aaron S Kesselheim; Jessica A Myers; Daniel H Solomon; Wolfgang C Winkelmayer; Raisa Levin; Jerry Avorn
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

7.  Compassionate use of orphan drugs.

Authors:  Hanna I Hyry; Jeremy Manuel; Timothy M Cox; Jonathan C P Roos
Journal:  Orphanet J Rare Dis       Date:  2015-08-21       Impact factor: 4.123

8.  Principles for consistent value assessment and sustainable funding of orphan drugs in Europe.

Authors:  Laura Gutierrez; Julien Patris; Adam Hutchings; Warren Cowell
Journal:  Orphanet J Rare Dis       Date:  2015-05-03       Impact factor: 4.123

9.  Cost-effectiveness of enzyme replacement therapy for Fabry disease.

Authors:  Saskia M Rombach; Carla E M Hollak; Gabor E Linthorst; Marcel G W Dijkgraaf
Journal:  Orphanet J Rare Dis       Date:  2013-02-19       Impact factor: 4.123

Review 10.  Imiglucerase in the treatment of Gaucher disease: a history and perspective.

Authors:  Patrick B Deegan; Timothy M Cox
Journal:  Drug Des Devel Ther       Date:  2012-04-18       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.